Pharma Capital
EPIC: VEC
Market: AIM
52-week High/Low: 166.97p / 88.90p
Sector: Pharma & Biotech
Market Cap: 676.83M

Vectura Group plc, (Vectura) along with its subsidiaries, is principally engaged in the research and development of therapeutic products and drug delivery systems for human use. The Company is focused on the development of inhaled pharmaceuticals. It has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to pharmaceutical companies. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis. It has development collaborations with a range of pharmaceutical companies, including Boehringer Ingelheim, Novartis and Chiesi. On January 18, 2007, Vectura acquired Innovata plc and its subsidiaries.

Vectura Group is traded in the ISDX Exchange HERE

Vectura Group PLC

www.vectura.co.uk

Interactive graph

col 3
col 4
col 5
col 6

Vectura Group PLC Timeline

View All

Market Reports Including VEC

VIEW ALL

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.